Hemosol

HML-T

0.00
0.00 (0.00%)
This company is not ACTIVE.

Analysis and Opinions about HML-T

Signal
Opinion
Expert
DON'T BUY
DON'T BUY
August 9, 2005
This could be a time when money moves back into the health care. Usually the small cap biotech stocks, such as Biovale (BVF-T), Patheon (PTI-T), MDS (MDS-T), etc. move together. Don't just buy one, buy 3 or 4 of them. This one is a pretty thin trader, so would stay away from it.
Hemosol (HML-T)
August 9, 2005
This could be a time when money moves back into the health care. Usually the small cap biotech stocks, such as Biovale (BVF-T), Patheon (PTI-T), MDS (MDS-T), etc. move together. Don't just buy one, buy 3 or 4 of them. This one is a pretty thin trader, so would stay away from it.
Bill Carrigan
Technical Analyst, Getting Technical Info Service
Price
$1.500
Owned
Unknown
DON'T BUY
DON'T BUY
June 13, 2005
Consolidated stock at 4 to 1 to meet Nasdaq requirements. Markets hate reverse consolidations. Typically it's not a good sign as it means you've got too many shares outstanding. Not a great company, so wouldn't expect a whole lot from this company in the future.
Hemosol (HML-T)
June 13, 2005
Consolidated stock at 4 to 1 to meet Nasdaq requirements. Markets hate reverse consolidations. Typically it's not a good sign as it means you've got too many shares outstanding. Not a great company, so wouldn't expect a whole lot from this company in the future.
Peter Hodson
CEO & Head of Research, 5i Research Inc.
Price
$1.750
Owned
No
VAGUE
VAGUE
February 9, 2004
Speculative future.
Hemosol (HML-T)
February 9, 2004
Speculative future.
Michael Sprung
President, Sprung Investment Management
Price
$1.580
Owned
Unknown
BUY
BUY
January 28, 2004
It will expire again, company has run out of money many times. Take money out, while money is on the table.
Hemosol (HML-T)
January 28, 2004
It will expire again, company has run out of money many times. Take money out, while money is on the table.
Andrew McCreath
Senior Portfolio Manager, Sentry Select Capital
Price
$1.620
Owned
Unknown
SELL
SELL
January 26, 2004
Basically, you are paying for an option. The company has run out of money many times and they continue to have regulatory problems with their product.
Hemosol (HML-T)
January 26, 2004
Basically, you are paying for an option. The company has run out of money many times and they continue to have regulatory problems with their product.
Andrew McCreath
Senior Portfolio Manager, Sentry Select Capital
Price
$1.560
Owned
No
DON'T BUY
DON'T BUY
December 15, 2003
Built a nice plant in Mississauga, but found they had trouble with their blood substitute. Now a speculative stock.
Hemosol (HML-T)
December 15, 2003
Built a nice plant in Mississauga, but found they had trouble with their blood substitute. Now a speculative stock.
Gavin Graham
Trustee, Pointbreak ETFs
Price
$1.580
Owned
No
DON'T BUY
DON'T BUY
December 8, 2003
Have made arrangements with another biotech company by contracting for part of their facility. Should be getting some revenues. Not a fan.
Hemosol (HML-T)
December 8, 2003
Have made arrangements with another biotech company by contracting for part of their facility. Should be getting some revenues. Not a fan.
Robert Floyd
President, R A Floyd Management
Price
$1.700
Owned
No
DON'T BUY
DON'T BUY
December 8, 2003
A speculative play. Hemalink stalled in face two clinical trials. Build a plant. Limited visibility going forward.
Hemosol (HML-T)
December 8, 2003
A speculative play. Hemalink stalled in face two clinical trials. Build a plant. Limited visibility going forward.
John Sinkins, CFA
Senior Portfolio Manager, Sentry Select Capital Corp
Price
$1.700
Owned
Unknown
DON'T BUY
DON'T BUY
September 5, 2003
Ran into trouble with their lead product. Down to about $900,000 in cash. The company is on life support.
Hemosol (HML-T)
September 5, 2003
Ran into trouble with their lead product. Down to about $900,000 in cash. The company is on life support.
Lou Schizas
Business Editor, Market Call
Price
$0.870
Owned
Unknown
DON'T BUY
DON'T BUY
March 31, 2003
Very speculative. FDA trials didn't go well.
Hemosol (HML-T)
March 31, 2003
Very speculative. FDA trials didn't go well.
John Sinkins, CFA
Senior Portfolio Manager, Sentry Select Capital Corp
Price
$0.720
Owned
Unknown
DON'T BUY
DON'T BUY
March 17, 2003
A lot of problems. May not survive.
Hemosol (HML-T)
March 17, 2003
A lot of problems. May not survive.
Glenn Paradis, BA, CFA
Vice President & Sr Portfolio Manager, Equities, Aegon Capital Management Inc.
Price
$0.620
Owned
Unknown
DON'T BUY
DON'T BUY
January 14, 2003
A long way from being a mature company with mature products. Speculative.
Hemosol (HML-T)
January 14, 2003
A long way from being a mature company with mature products. Speculative.
David Baskin
President, Baskin Wealth Management
Price
$2.890
Owned
Unknown
DON'T BUY
DON'T BUY
January 14, 2003
Never seems to get it together.
Hemosol (HML-T)
January 14, 2003
Never seems to get it together.
Michael Smedley
Exec VP & Chief Investment Officer, Morgan Meighan & Associates
Price
$2.890
Owned
Unknown
DON'T BUY
DON'T BUY
December 5, 2002
Worst is behind them. Would prefer owning through MDS.
Hemosol (HML-T)
December 5, 2002
Worst is behind them. Would prefer owning through MDS.
John Zechner
Chairman, J. Zechner & Assoc
Price
$2.500
Owned
Unknown
WEAK BUY
WEAK BUY
November 7, 2002
OK for a long term hold. Buy on weakness.
Hemosol (HML-T)
November 7, 2002
OK for a long term hold. Buy on weakness.
Bruce Campbell (1)
President, Campbell and Lee InvMngmnt
Price
$1.900
Owned
Unknown
DON'T BUY
DON'T BUY
November 1, 2002
Has some problems. Cash position is down to one year. If they issue stocks to rais cash, it will dilute these shares further.
Hemosol (HML-T)
November 1, 2002
Has some problems. Cash position is down to one year. If they issue stocks to rais cash, it will dilute these shares further.
Robert Floyd
President, R A Floyd Management
Price
$1.290
Owned
Unknown
DON'T BUY
DON'T BUY
October 2, 2002
Very risky situation. May have to dilute stock by issuing more shares.
Hemosol (HML-T)
October 2, 2002
Very risky situation. May have to dilute stock by issuing more shares.
Mike Weir
Managing Director, Guardian Capital
Price
$1.130
Owned
Unknown
DON'T BUY
DON'T BUY
September 20, 2002
Could run out of cash.
Hemosol (HML-T)
September 20, 2002
Could run out of cash.
Gavin Graham
Trustee, Pointbreak ETFs
Price
$0.850
Owned
Unknown
DON'T BUY
DON'T BUY
August 20, 2002
Had delays in getting product out. A lot of cash. Risky unless you buy several small pharmaceuticals to spread the risk.
Hemosol (HML-T)
August 20, 2002
Had delays in getting product out. A lot of cash. Risky unless you buy several small pharmaceuticals to spread the risk.
Gavin Graham
Trustee, Pointbreak ETFs
Price
$1.070
Owned
Unknown
DON'T BUY
DON'T BUY
August 19, 2002
Has cash burn and has to raise money. Speculative.
Hemosol (HML-T)
August 19, 2002
Has cash burn and has to raise money. Speculative.
David Baskin
President, Baskin Wealth Management
Price
$1.030
Owned
Unknown
DON'T BUY
DON'T BUY
May 2, 2002
Have had a tough time getting approval. Competition is growing. Future is uncertain.
Hemosol (HML-T)
May 2, 2002
Have had a tough time getting approval. Competition is growing. Future is uncertain.
Bruce Cooper
Portfolio Manager, T.D. Asset
Price
$3.750
Owned
Unknown
DON'T BUY
DON'T BUY
April 29, 2002
Hard to like.
Hemosol (HML-T)
April 29, 2002
Hard to like.
Michael Smedley
Exec VP & Chief Investment Officer, Morgan Meighan & Associates
Price
$3.900
Owned
Unknown
DON'T BUY
DON'T BUY
April 25, 2002
Disappointed with their product results. High burn rate.
Hemosol (HML-T)
April 25, 2002
Disappointed with their product results. High burn rate.
Robert Floyd
President, R A Floyd Management
Price
$4.000
Owned
Unknown
DON'T BUY
DON'T BUY
April 18, 2002
Has disappointed. Not convinced about the needs for blood substitute.
Hemosol (HML-T)
April 18, 2002
Has disappointed. Not convinced about the needs for blood substitute.
Glenn Paradis, BA, CFA
Vice President & Sr Portfolio Manager, Equities, Aegon Capital Management Inc.
Price
$4.600
Owned
Unknown
DON'T BUY
DON'T BUY
April 3, 2002
Treat as a trading stock. No value right now.
Hemosol (HML-T)
April 3, 2002
Treat as a trading stock. No value right now.
David Driscoll
President & CEO, Liberty International Investment Management Inc
Price
$4.580
Owned
Unknown
DON'T BUY
DON'T BUY
April 2, 2002
Only has one drug. Needds more diversification.
Hemosol (HML-T)
April 2, 2002
Only has one drug. Needds more diversification.
Joe Connolly
Director of Resource and Trading, Cockfield Porretti Cunningham
Price
$4.620
Owned
Unknown
DON'T BUY
DON'T BUY
March 21, 2002
Approval of Hemolink was denied. No revenues or earnings.
Hemosol (HML-T)
March 21, 2002
Approval of Hemolink was denied. No revenues or earnings.
Bruce Cooper
Portfolio Manager, T.D. Asset
Price
$4.200
Owned
Unknown
DON'T BUY
DON'T BUY
March 21, 2002
Too much competition.
Hemosol (HML-T)
March 21, 2002
Too much competition.
Joe Connolly
Director of Resource and Trading, Cockfield Porretti Cunningham
Price
$4.200
Owned
Unknown
BUY
BUY
March 20, 2002
At a good price and a good buy for an aggressive investor.
Hemosol (HML-T)
March 20, 2002
At a good price and a good buy for an aggressive investor.
Rob Callander
Vice President and Portfolio Manager, Caldwell Securities
Price
$5.880
Owned
Unknown
DON'T BUY
DON'T BUY
February 19, 2002
A one trick pony. Speculative.
Hemosol (HML-T)
February 19, 2002
A one trick pony. Speculative.
David Baskin
President, Baskin Wealth Management
Price
$6.290
Owned
Unknown
DON'T BUY
DON'T BUY
January 23, 2002
Have ahd difficulties in their trials. May have a weak cash position.
Hemosol (HML-T)
January 23, 2002
Have ahd difficulties in their trials. May have a weak cash position.
Mike Weir
Managing Director, Guardian Capital
Price
$7.450
Owned
Unknown
DON'T BUY
DON'T BUY
January 9, 2002
Starting to move up, but prefers to wait for the product to start selling.
Hemosol (HML-T)
January 9, 2002
Starting to move up, but prefers to wait for the product to start selling.
David Driscoll
President & CEO, Liberty International Investment Management Inc
Price
$9.000
Owned
Unknown
BUY
BUY
December 31, 2001
A long term situation, but expects it will do OK.
Hemosol (HML-T)
December 31, 2001
A long term situation, but expects it will do OK.
Malvin Spooner
Chairman and Chief Executive Officer, Mavrix Fund Management
Price
$7.350
Owned
Unknown
BUY
BUY
December 28, 2001
Sees it going up. Use a $6.90 stop loss. Expects it to get to $8.75 at which time it should be looked at again.
Hemosol (HML-T)
December 28, 2001
Sees it going up. Use a $6.90 stop loss. Expects it to get to $8.75 at which time it should be looked at again.
Brian Acker, CA
Chief Executive Officer, President and Chief Inves, Acker Finley Inc.
Price
$7.490
Owned
Unknown
WAIT
WAIT
December 21, 2001
A lot of competition in blood substitutes.
Hemosol (HML-T)
December 21, 2001
A lot of competition in blood substitutes.
Robert Floyd
President, R A Floyd Management
Price
$7.400
Owned
Unknown
DON'T BUY
DON'T BUY
December 6, 2001
Prefers other companies that have earnings. Might buy at $3.
Hemosol (HML-T)
December 6, 2001
Prefers other companies that have earnings. Might buy at $3.
Brian Acker, CA
Chief Executive Officer, President and Chief Inves, Acker Finley Inc.
Price
$5.900
Owned
Unknown
DON'T BUY
DON'T BUY
November 28, 2001
Wait for FDA approval.
Hemosol (HML-T)
November 28, 2001
Wait for FDA approval.
Joe Connolly
Director of Resource and Trading, Cockfield Porretti Cunningham
Price
$6.020
Owned
Unknown
DON'T BUY
DON'T BUY
November 27, 2001
If you own, hold.
Hemosol (HML-T)
November 27, 2001
If you own, hold.
John Zechner
Chairman, J. Zechner & Assoc
Price
$6.250
Owned
Unknown
DON'T BUY
DON'T BUY
November 26, 2001
Watch how the trials go.
Hemosol (HML-T)
November 26, 2001
Watch how the trials go.
Fred Ketchen
Managing Director, Scotia McLeod
Price
$6.400
Owned
Unknown
WEAK BUY
WEAK BUY
November 22, 2001
Analysts are expecting a large upside. Will take time to get through the FDA phases.
Hemosol (HML-T)
November 22, 2001
Analysts are expecting a large upside. Will take time to get through the FDA phases.
Robert Floyd
President, R A Floyd Management
Price
$6.500
Owned
Unknown
DON'T BUY
DON'T BUY
November 5, 2001
Wait for FDA approval to go through. Will be a good product.
Hemosol (HML-T)
November 5, 2001
Wait for FDA approval to go through. Will be a good product.
David Driscoll
President & CEO, Liberty International Investment Management Inc
Price
$4.800
Owned
Unknown
BUY
BUY
October 25, 2001
A worthwhile stock to own a little bit. At a good price.
Hemosol (HML-T)
October 25, 2001
A worthwhile stock to own a little bit. At a good price.
Brendan Caldwell
President, Caldwell Securities
Price
$6.450
Owned
Unknown
WEAK BUY
WEAK BUY
October 11, 2001
Good product. Phase 3is delayed for a year. Lots of competition, but room for all. Speculative.
Hemosol (HML-T)
October 11, 2001
Good product. Phase 3is delayed for a year. Lots of competition, but room for all. Speculative.
Richard Stone
President, Stone Funds
Price
$5.980
Owned
Unknown
DON'T BUY
DON'T BUY
September 7, 2001
Will take a while for the product to come on stream. Has strong competition.
Hemosol (HML-T)
September 7, 2001
Will take a while for the product to come on stream. Has strong competition.
Fred Ketchen
Managing Director, Scotia McLeod
Price
$4.470
Owned
Unknown
DON'T BUY
DON'T BUY
September 5, 2001
High valuation and delay on trials was a downer.
Hemosol (HML-T)
September 5, 2001
High valuation and delay on trials was a downer.
Ian Nakamoto
Director of Research, MacDougall, MacDougall & MacTier
Price
$4.700
Owned
Unknown
DON'T BUY
DON'T BUY
September 4, 2001
Phase 3 stage required restructuring so competitors now have a year's head start.
Hemosol (HML-T)
September 4, 2001
Phase 3 stage required restructuring so competitors now have a year's head start.
Richard Stone
President, Stone Funds
Price
$5.050
Owned
Unknown
DON'T BUY
DON'T BUY
August 31, 2001
Biotechs can have a drop if the core product doesn't work out. Speculative.
Hemosol (HML-T)
August 31, 2001
Biotechs can have a drop if the core product doesn't work out. Speculative.
David Baskin
President, Baskin Wealth Management
Price
$5.460
Owned
Unknown
WEAK BUY
WEAK BUY
August 24, 2001
Will be 6/9 months before getting approval. Good price.
Hemosol (HML-T)
August 24, 2001
Will be 6/9 months before getting approval. Good price.
Gavin Graham
Trustee, Pointbreak ETFs
Price
$6.350
Owned
Unknown
DON'T BUY
DON'T BUY